Form 4: Rhythm Pharma CSO Granted 41,650 Equity Awards

Rhythm Pharmaceuticals' Chief Scientific Officer, Alastair Garfield, received 16,650 Restricted Stock Units and 25,000 stock options on February 11, 2026.

Summary

• Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals, Inc. (RYTM), was granted equity awards on February 11, 2026.
• The awards include 16,650 Restricted Stock Units (RSUs) and 25,000 stock options.
• Each RSU represents a contingent right to receive one share of Issuer common stock.
• The RSUs vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.
• The stock options have an exercise price of $98.47 and expire on February 10, 2036.
• The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at retaining key talent and aligning interests, without indicating any immediate operational or financial changes.

Positives

• The grant of equity awards to a key executive like the Chief Scientific Officer aligns management's interests with long-term shareholder value.
• The multi-year vesting schedules for both RSUs and stock options incentivize the executive's continued service and performance.

Negatives

• The stock options' exercise price of $98.47 means the company's stock price must appreciate above this level for the options to be 'in the money' and provide value to the executive.
• The awards are future-oriented incentives and do not represent immediate cash compensation or direct stock purchases by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Scientific Officer are a standard practice in the biotechnology and pharmaceutical industries. These grants are designed to retain talent, incentivize innovation, and align executive performance with long-term shareholder value, especially crucial in R&D-intensive sectors where long development cycles are common.

Related Party Transactions

• The filing details an equity grant to Alastair Garfield, the Chief Scientific Officer, which is a standard compensation-related transaction between an executive and the company.

Stakeholder Impact

• Shareholders: The equity grants, while dilutive over time as they vest and are exercised, serve to align the Chief Scientific Officer's financial interests with the long-term performance and share price appreciation of the company.
• Employees: May signal stability and continued investment in key leadership, potentially boosting morale and confidence in the company's direction.
• Management: Alastair Garfield's compensation package is enhanced with long-term incentives, reinforcing his commitment to the company's strategic goals and scientific advancements.

Next Steps

• Alastair Garfield's continued service to the Issuer to meet the specified vesting conditions for both the Restricted Stock Units and stock options.
• Future Form 4 filings will report any exercises of options or sales of shares by the reporting person.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment stance. The grants align executive incentives with long-term shareholder value, which is generally positive, but not a catalyst for a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, Alastair Garfield, Chief Scientific Officer, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Form 4, Biotechnology, Pharmaceuticals